Genome-wide DNA methylation in an animal model and human studies of schizophrenia: a protocol for a meta-analysis

Thabo Magwai, Fredrick Otieno Oginga, Bonginkosi Chiliza, Thabisile Mpofana, Khethelo Richman Xulu

ABSTRACT

Introduction and objective Neuropsychiatric disorders like schizophrenia are heterogeneous in that they occur because of the interaction of factors. These factors include but are not limited to genetic, epigenetic, neurobiological and environmental factors. Methylation of DNA, like other epigenetic modifications, is risk factors for neuropsychiatric disorders. Candidate gene approach projects have produced contradictory results to find candidate gene methylation. The current genome-wide studies have limitations.

Search strategy An exhaustive search strategy was designed to recover studies on genome-wide DNA methylation in schizophrenia patients or schizophrenia rat models. The Medline (PubMed), SCOPUS and Web of Science, databases were searched, giving 4077 references in total.

Screening and annotation Studies will undergo two phases of screening, title and abstract screening and article screening, for inclusion by two reviewers. A third reviewer will resolve any disagreements in the article screening phase. Data will be collected using the Systematic Review Facility (http://syrf.org.uk/) tool. All included studies will undergo study quality and risk of bias assessment.

Data management and reporting Data will be extracted and used to calculate effect sizes. For the purpose of this meta-analysis, a random effects model will be used to combine effect sizes. Heterogeneity will be assessed, and the sources identified. A risk-of-bias assessment will be carried out to assess the quality of the studies. An assessment of publication bias will also be carried out.

Ethics and dissemination No ethical approval is required as there are no participants in the study. We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and disseminate the findings through publication and conference presentation.

PROSPERO registration number CRD42021283159.

INTRODUCTION

Schizophrenia is defined as a mental illness whose attributes include disconnection of thoughts, ideas, identity and emotions. The symptoms of the disease, both positive and negative, are due to dysregulation of the neural pathways. Despite the increased research in the field schizophrenia, there remains still a gap in knowledge related to the pathophysiology, biomarkers for the prediction of the onset of schizophrenia. The heritability schizophrenia has been approximated to range from 79% to 81%. It has been hypothesised that this may be because schizophrenia genetic risk loci are found in the introns and promoter gene regions, leading to a suspicion that the regulation of genes may be of importance in the development of the disease. The risk loci are thus thought to be linked to the expression of genes, thus suggesting that epigenetics is an arbitrator of genetic risk in the development of schizophrenia.

DNA methylation is the most documented epigenetic marker. DNA methylation is evident by the attachement of a methyl group at the cytosine-guanine dyads (CpG) dinucleotide. Initially, DNA methylation projects interrogated alterations in candidate genes like RELN, COMT and GAD67. Due to conflicting results with candidate genes, researchers opted for genome-wide DNA methylation methods for a more comprehensive whole-genome coverage than methylation of a targeted gene. Even with the growing number of genome-wide methylation studies, there remains still a problem with the pinpointing consistent schizophrenia-specific DNA methylation patterns. This challenge is due to the lack of repeatability of results in genome-wide studies. This lack of reproducibility has been thought to be due various limitations of studies in current literature. The current limitations are the small sample size, the type of samples used for analysis, medication use, smoking, tissue and cell-type heterogeneity and epigenetic methods used. One way to mitigate the effects of
these limitations is to perform a meta-analysis, which will provide a clear picture of previously conducted studies and provide future directions for further investigations.

METHODS
Research question and search strategy
This review aims to assess and summarise the findings of studies that characterised the genome-wide DNA methylation in patients or rodent models with schizophrenia compared with controls. The study will also explore the possibility of blood-based DNA methylation as a biomarker for schizophrenia diagnosis, prognosis or therapeutic marker.

Objectives
1. To determine differentially methylated regions (DMR) or positions (DMP) in humans or rodents models of schizophrenia compared with those without schizophrenia.
2. To determine the common DMR or DMP related to schizophrenia, controlled for common cofounders.
3. To determine DMRs or DMPs related to schizophrenia that is common between brain tissue and peripheral tissue.

Searches
The MEDLINE (PubMed), Web of Science and Scopus databases will be used for the electronic search of published studies. The searches will be from inception to 30 September 2021. The search will be limited only to publications in the English language and any publication that can be converted to English. Keywords were chosen based on the combinations of terms for schizophrenia and genome-wide DNA methylation. The search strategy used is listed in table 1. A manual search of the reference lists of included studies and relevant reviews related to the study question will be conducted to identify additional articles for inclusion.

Study selection and inclusion/exclusion criteria
All original research articles, with no restrictions on the date, will be included, which reported genome-wide DNA methylation in schizophrenia patients or schizophrenia rat models. Studies using brain tissue and peripheral tissue (blood) will be included. Rodent studies that used schizophrenia treatment will be included in the meta-analysis. The meta-analysis will consist of male and female participants in human and rodent studies. Only animal models using rodents will be included in the meta-analysis. Exclusion criteria to be used are as follows: studies written in other languages either than English and cannot be translated to English, articles that have no full text available (even after an attempts to acquire the full text from the author), studies with no new data like review articles, systematic reviews, book chapters and conference abstracts, and studies that used targeted gene approaches and not genome wide approach. The review will also exclude case studies, cross-over studies, studies with no separation of control group, in vitro studies, ex vivo studies and studies using in silico models for schizophrenia investigation.

The selection of studies will include two screening phases, the title and abstract screening phase and the article screening phase. For the title and abstract screening phase, studies obtained from the database searches will undergo title and abstract screening by two independent researchers. Any study selected by at least one reviewer will go through full-text screening. The full text will be obtained from all the studies that passed the title and abstract screening for the article screening phase. Two researchers will independently assess the full text for eligibility. The third reviewer will resolve any discrepancies between the two reviewers.

Collection of study characteristics
The Systematic Review and Meta-analysis Facility (SyRF) platform (http://syrf.org.uk/) will be used to the collect of qualitative and quantitative data from the included studies. Studies will be imported to the SyRF platform (app.syrf.org.uk) for annotation and extraction of data. Annotations include characteristics of (1) animals or patients (species, strain, age, sex, age at diagnosis (humans), tobacco smoking, cause of death, alcohol use (humans)), (2) control and schizophrenia genome-wide DNA methylation, (3) medication use (human studies) or schizophrenia induction (animal studies) (name, dose,
mode of administration, duration of administration), (4) of experimental designs (genome-wide DNA methylation used, CpG and/or non-CpG coverage, sample size, tissue and/or cell type used for analysis), (5) cognitive outcomes measured or symptoms of patients (where possible) (like behaviour task performed, timing of outcome assessment relative to diet/intervention administration, symptoms for humans) and (6) additional (eg, transcriptomics data, other reported omics) outcomes reported.

**Study quality appraisal and risk of bias**

Studies will be assessed for selection bias, performance bias, detection bias, attrition bias (for animal studies), reporting bias and other biases. Using the CAMARADES checklist for study quality, adapted as follows: The Downs and Black checklist will be used for the assessment of quality and preferences. The checklist comprises four domains, namely, the reporting of bias, external validity, internal validity and selection bias. The scores are categorised as excellent (score between 26 and 27), good (score between 20 and 25), fair (score between 15 and 19) and poor (score between 0 and 14). Additionally, a modified version of the Systematic Review Centre for Laboratory animal Experimentation will be used to assess risk bias for animal studies.

**Extraction of outcome data**

For animal studies, outcome data will be collected for behavioural tests, including an examination of executive function, learning, and spatial and non-spatial memory. Outcome data will be collected for mental health diagnosis studies using human participants. For each study, the significant DMR’s or DMP’s with an false discovery rate (FDR) cut off of 0.05, genomic position of DMR’s, FDR, affected genes and correlation value will be collected. Additionally, sample size, species origin of samples used, cell or tissue type used, the method used for DNA methylation assessment will be extracted. Should there not be any issues with results from different methods, the results will be controlled for themethod used statistically or by study selection. For studies using human samples, different outcomes like age of diagnosis, medication use, tobacco smoking, other diagnoses for patients with multiple mental disorders diagnosis and use of drugs will be collected. For animal’s studies, outcomes like the method of inducing schizophrenia, results of behavioural testing and species of animal used will be reported. The type of medication used for both rodents and human studies where medication/treatment was used will be collected. Additionally, data on covariates, such as differentially expressed genes (DEG’s), microRNA, proteomics and metabolomics, will also be collected where they are reported.

Quantitative data will be extracted from the study using either a digital ruler tool or the embedded Graph2Data tool, if available. Missing values will not be imputed. Authors will be contacted for further information if all data cannot be ascertained. The authors of studies will be reached where inadequate data are provided to acquire enough information. Extracted data will be managed using Review Manager.

**Quantitative analysis**

STATA V.17.0 software will be used for statistical analysis. Pooled risk ratios (RRs) will be determined and reported with a 95% CI. For dichotomous data, an RR with a 95% CI will be measured. The RR has been shown to be more instinctive than OR. For continuous data, a weighted means differences (with 95% CI) will be used. Standardised mean differences (95% CI) will be used in the event that of different measures. For skewed data and qualitative data, adescriptive presentation will be used.

**Heterogeneity**

The heterogeneity will be quantified by using $\chi^2$ test and $I^2$ metric. A random effect model priori will be used in the study. A random effect model has been chosen as the conclusion will be generalised beyond the included studies. Any decrease in heterogeneity will be determined using subgroup analysis for categorical data and meta-regression analysis for continuous data. A narrative synthesis will be presented for any variables with insufficient homogeneity or if the data are insufficient for meta-analysis.

**Analysis of subgroups or subsets**

Depending on the number of studies, a subgroup analysis will be performed with a minimum of two studies for a meta-analysis. Suppose an adequate number of studies for a meta-analysis, subgroup analysis will be performed. The following subgroups will be investigated if possible:

1. Human postmortem brain tissue compared with those without schizophrenia.
2. Human peripheral tissue (blood) compared with those without schizophrenia.
3. Animal brain tissue compared with those without schizophrenia.
4. Animal peripheral tissue (blood) compared with those without schizophrenia.
5. Common DMR’s or DMP’s in brain tissue and peripheral tissue for animals and humans.
6. Common traits like common medications and tobacco use compared controls.

An exploratory analysis will be performed to estimate how moderators of interest to the literature may influence results. We will explore the relationship between factors like age, use of medication, smoking and symptom severity, results of the behavioural test (animal studies) on genome-wide methylation differences between participants with schizophrenia and comparison groups. The effects of moderators will be assessed by Bayesian hierarchical models (meta-regression).

**Sensitivity and publication bias**

Publication bias will be tested by using the funnel plot analyses, and the Egger method will be used to quantify publication bias. The trim-and-fill methods will be used
to determine the impact of publication bias where there is publication bias.

DISCUSSION
Preclinical systematic reviews and meta-analyses are valuable tools in combining large numbers of projects’ data with conflicting results as seen in genome-wide DNA methylation studies. These reviews can address limitations and help guide the design and content of future preclinical research and human clinical studies.35 Genome-wide DNA methylation studies suffer from complications with the reproduction of results. This challenge is due to sample size, type of sample used, medication use,27 tobacco smoking,29 tissue and cell heterogeneity,30 and DNA methylation methods used.31 Also, these studies have used different samples from human schizophrenia patients and various animal models for schizophrenia. Other studies have also captured additional data like transcriptomic data, medication use, further diagnosis, sample and tissue.

Strengths and limitations
The study’s strength is that it will review data from both human participants and rodents with schizophrenia. The study intends to conduct a meta-regression in both groups and compare the outcomes of the two groups. Furthermore, with our subgroup analysis, we could gather information on potential biomarkers for schizophrenia. The review also has some potential limitations. The first limitation is that the included studies might have high variability in their experimental designs and conduct, which may influence and report the analyses. The second limitation is that the summary effect size may be overestimated due to publication bias. However, this could be addressed by using statistical methods to calculate a true estimate of the effect, filtering out the influence of publication bias.

Author affiliations
1Department of Physiology, University of KwaZulu-Natal College of Health Sciences, Durban, South Africa
2Department of Chemical Pathology, University of KwaZulu-Natal College of Health Sciences, Durban, South Africa
3Department of Clinical Medicine, Kabarak University, Nakuru, Kenya
4Department of Psychiatry, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa
5School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Johannesburg-Braamfontein, Gauteng, South Africa

Contributors
TMa: topic selection, study conceptualisation and design, systematic review execution (main reviewer), manuscript writing; FDO: systematic review execution (second reviewer); BC: methodology, study conceptualisation and design, manuscript writing; TMp: topic selection, study conceptualisation and design, manuscript writing and statistical review execution (third reviewer). All authors contributed to manuscript review and preparation before submission.

Funding
This research was supported by the National Research Foundation Thuthuka grant number (118049) (KRK), National Research Foundation Thuthuka grant number (129827) (TMa) and Developing Research Innovation, Localisation and Leadership in South Africa (DRILL), grant number (D43TW010131) (TMp).

Competing interests
None declared.

REFERENCES
1 Moskowitz A, Heim G. Eugen Bleuler’s dementia praecox or the group of schizophrenias (1911): a centenary appreciation and reconsideration. Schizophr Bull 2011;37:471–9.
2 Kim JS, Shin KS, Jung WH, et al. Power spectral aspects of the default mode network in schizophrenia: an MEG study. BMC Neurosci 2014;15:104.
3 Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016;388:86–97.
4 Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci 2017;18:727–40.
5 Magwai T, Shangease KB, Oginga FO, et al. DNA methylation and schizophrenia: current literature and future perspective. Cells 2021;10. doi:10.3390/cells10112890. [Epub ahead of print: 26 10 2021].
6 Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet 2014;383:1677–87.
7 Wong AHC, Van Tol HMM. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003;27:269–306.
8 Kaur Multani P, Saini N, Kaur R. Chapter 59 - Biomarkers for drugs of abuse and neuropsychiatric disorders: Models and mechanisms. In: Gupta RC, ed. Biomarkers in toxicology. Boston: Academic Press, 2014: 983–1001.
9 Perkovic M, Erjavec G, Strac D, et al. Theranostic biomarkers for schizophrenia. Int J Mol Sci 2017;18:733.
10 SL O, Vicnesh J, Ciaccio EJ. Deep Convolutional neural network model for automated diagnosis of schizophrenia using EEG signals. Applied Sciences 2019;9:2870.
11 Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–92.
12 Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009;373:234–9.
13 Hilkre R, Helenius D, Fagerlund B, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register. Biol Psychiatry 2018;83:492–8.
14 Mendizabal I, Berto S, Usui N, et al. Cell type-specific epigenetic links to schizophrenia risk in the brain. Genome Biol 2019;20:135.
15 Froemer M, Roussos P, Sieberts SK, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 2016;19:1442–53.
16 Gusev A, Mancuso N, Won H, et al. Transcriptome-Wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet 2018;50:338–48.
17 Jaffe AE, Straub RC, Shin JH, et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci 2018;21:1117–25.
Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425–32.

Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9:465–76.

Zeng Y, Chen T. DNA methylation reprogramming during mammalian development. Genes 2019;10:257.

Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14:204–20.

Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A 2005;102:9341–6.

Tamura Y, Kunugi H, Ohashi J, et al. Epigenetic aberration of the human REELIN gene in psychiatric disorders. Mol Psychiatry 2007;12:593–600.

Mill J, Dempster E, Caspi A, et al. Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet B Neuropsychiatr Genet 2006;141B:421–5.

Gavin DP, Sharma RP. Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 2010;34:862–8.

Richetto J, Massart R, Weber-Stampfle U, et al. Genome-Wide DNA methylation changes in a mouse model of infection-mediated neurodevelopmental disorders. Biol Psychiatry 2017;81:265–76.

Nishioka M, Bundo M, Kasai K, et al. DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Med 2012;4:96.

Swathy B, Banerjee M. Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy. Epigenomics 2017;9:721–36.

Marzi SJ, Sugden K, Arseneault L, et al. Analysis of DNA methylation in young people: limited evidence for an association between victimization stress and epigenetic variation in blood. Am J Psychiatry 2018;175:517–29.

Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol 2014;15:R31–9.

Dempster E, Viana J, Pidsley R, et al. Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schizophr Bull 2013;39:11–16.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377–84.

Hooper P, Jutai JW, Strong G, et al. Age-Related macular degeneration and low-vision rehabilitation: a systematic review. Can J Ophthalmol 2008;43:180–7.

Sterne JA. Meta-Analysis in Stata: an updated collection from the Stata Journal. StataCorp LP, 2009.